Physician profile
Kun Chen
NPI 1730380056
$21,696.26
in general payments reported to CMS, 2019-2025
41 companies · $3,238 in 2025
The $3,238 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,458 · 2020: $1,894 · 2021: $3,142 · 2022: $3,537 · 2023: $3,620 · 2024: $2,806 · 2025: $3,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,373 · Consulting Fee: $180 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,372.64 |
| Consulting Fee | $180.00 |
| Education | $112.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,392.38 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $3,095.50 | 2019-2025 | Evenity, Enbrel, Prolia |
| Ucb, INC. | $1,734.07 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,490.08 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,325.99 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $1,129.97 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Astrazeneca Pharmaceuticals Lp | $845.01 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $649.74 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $570.13 | 2019-2025 | Ofev, Cyltezo |
| Pfizer INC. | $569.59 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $516.92 | 2022-2023 | Acthar |
| Genentech USA, INC. | $456.05 | 2019-2025 | Gazyva, Actemra |
| Fresenius Kabi USA, LLC | $321.25 | 2023-2024 | Idacio |
| Celgene Corporation | $313.41 | 2019 | |
| Radius Health, INC. | $275.88 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kun Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.